Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVO for Initial Therapy of Chronic Lymphocytic Leukemia
NCT03580928Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2018
- Primary completion
- Apr 2024
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1), venetoclax, obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Dana-Farber Cancer Institute. Started Aug 2018; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)venetoclaxobinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03580928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03580928.